Edris Badreddin
CIK: 0001786966
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 13,690 | $5K | 1/21/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 17,236 | $11K | 1/21/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,463 | $20K | 1/21/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 66,477 | $128K | 1/21/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 7,605 | $5K | 1/21/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 13,690 | $403K | 1/21/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 17,236 | $507K | 1/21/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 7,605 | $224K | 1/21/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 10,463 | $308K | 1/21/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 66,477 | $2.0M | 1/21/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.